ES2259207T3 - Nuevas combinaciones terapeuticas de mirtazapina y agentes antipsicoticos para el tratamiento o profilaxis de trastornos psicoticos. - Google Patents

Nuevas combinaciones terapeuticas de mirtazapina y agentes antipsicoticos para el tratamiento o profilaxis de trastornos psicoticos.

Info

Publication number
ES2259207T3
ES2259207T3 ES98919209T ES98919209T ES2259207T3 ES 2259207 T3 ES2259207 T3 ES 2259207T3 ES 98919209 T ES98919209 T ES 98919209T ES 98919209 T ES98919209 T ES 98919209T ES 2259207 T3 ES2259207 T3 ES 2259207T3
Authority
ES
Spain
Prior art keywords
mirtazapine
haloperidol
treatment
antipsychotic agent
risperidone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98919209T
Other languages
English (en)
Spanish (es)
Inventor
Christophorus Louis Eduard Broekkamp
Hermanus Henricus Gerardus Berendsen
Roger Martin Pinder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2259207T3 publication Critical patent/ES2259207T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES98919209T 1997-03-27 1998-03-25 Nuevas combinaciones terapeuticas de mirtazapina y agentes antipsicoticos para el tratamiento o profilaxis de trastornos psicoticos. Expired - Lifetime ES2259207T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97200881 1997-03-27
EP97200881 1997-03-27
EP97202785 1997-09-11
EP97202785 1997-09-11

Publications (1)

Publication Number Publication Date
ES2259207T3 true ES2259207T3 (es) 2006-09-16

Family

ID=26146283

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98919209T Expired - Lifetime ES2259207T3 (es) 1997-03-27 1998-03-25 Nuevas combinaciones terapeuticas de mirtazapina y agentes antipsicoticos para el tratamiento o profilaxis de trastornos psicoticos.

Country Status (24)

Country Link
EP (1) EP0969845B1 (https=)
JP (2) JP4377456B2 (https=)
KR (1) KR100577865B1 (https=)
CN (1) CN1226036C (https=)
AR (1) AR012193A1 (https=)
AT (1) ATE318604T1 (https=)
AU (1) AU726194B2 (https=)
BR (1) BR9808077A (https=)
CA (1) CA2284551C (https=)
CZ (1) CZ298105B6 (https=)
DE (1) DE69833645T2 (https=)
DK (1) DK0969845T3 (https=)
ES (1) ES2259207T3 (https=)
HU (1) HUP0002742A3 (https=)
ID (1) ID22283A (https=)
IL (1) IL123716A (https=)
NO (1) NO994673L (https=)
NZ (1) NZ337618A (https=)
PL (1) PL191449B1 (https=)
PT (1) PT969845E (https=)
RU (1) RU2222330C2 (https=)
TR (1) TR199902334T2 (https=)
TW (1) TW587938B (https=)
WO (1) WO1998043646A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
FR2797399B1 (fr) * 1999-08-13 2002-10-18 Aventis Pharma Sa Utilisation de la cyamemazine dans le traitement du sevrage aux benzodiazepines
FR2802101B1 (fr) * 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6350773B1 (en) 1999-12-10 2002-02-26 American Home Products Corporation Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
RU2268725C2 (ru) * 2000-01-19 2006-01-27 Акцо Нобель Н.В. Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств
US6495154B1 (en) 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
EP1795199A3 (en) * 2001-02-06 2007-07-25 AstraZeneca AB Quetiapine for the treatment of substance dependence or substance abuse
ATE360425T1 (de) 2001-02-06 2007-05-15 Astrazeneca Ab Verwendung von quetiapin für die behandlung von kokain-abhängigkeit
RU2232574C2 (ru) * 2002-04-05 2004-07-20 Новосибирский институт органической химии им. Н.Н.Ворожцова СО РАН Лекарственное средство для лечения различных форм депрессий "флуоглизин"
TW200517106A (en) 2003-10-29 2005-06-01 Wyeth Corp Sustained release pharmaceutical compositions
EP1547650A1 (en) * 2003-12-02 2005-06-29 B & B Beheer NV Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
SI1541197T1 (sl) * 2003-12-02 2009-08-31 Pharmaneuroboost N V Uporaba pipamperona in sndri, snri ali ssri za zdravljenje razpoloĺ˝enjskih ali tesnobnih motenj
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
BRPI0510657A (pt) 2004-06-03 2007-12-04 Hoffmann La Roche tratamento com cisplatina e com um inibidor de egfr
RU2445959C2 (ru) * 2006-06-09 2012-03-27 ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. Новый лейкопластырный препарат
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
DE102012011839B4 (de) * 2012-06-14 2018-03-22 Norbert Müller Verwendung von Interferon-gamma in einem Verfahren zur Behandlung von psychiatrischen Erkrankungen
RU2509560C1 (ru) * 2013-03-22 2014-03-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новые терапевтические комбинации миртазапина для применения при болевых расстройствах

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2410821A1 (de) * 1974-03-07 1975-09-18 Hoechst Ag Pharmazeutische kombinationspraeparate mit psychotroper wirkung und verfahren zu ihrer herstellung
CA1327008C (en) * 1988-01-15 1994-02-15 Walter Merz Anti-psychotic imidazobenzodiazepine
ATE99943T1 (de) * 1989-12-06 1994-01-15 Akzo Nv Psychotropische wirkstoffe enthaltende stabilisierte loesungen.
FI111367B (fi) * 1991-02-04 2003-07-15 Aventis Pharma Inc Menetelmä terapeuttisesti käyttökelpoisten N-(aryylioksialkyyli)heteroaryyli-8-atsabisyklo[3.2.1]oktaanijohdannaisten valmistamiseksi ja menetelmässä käytetyt välituotteet
ZA935078B (en) * 1992-07-15 1994-02-07 Nicolaas Johannes Jaco Loetter Pharmaceutical composition
RU2062114C1 (ru) * 1992-09-30 1996-06-20 Московский научно-исследовательский институт психиатрии МЗ РФ Способ лечения эндогенных психозов
CA2148823C (en) * 1992-11-17 1999-03-09 Welfide Corporation Sustained release microsphere preparation containing antipsychotic drug and production process thereof
JPH07242669A (ja) * 1994-03-07 1995-09-19 Akikazu Ogawa 四環系とブチロフェノン誘導体を化学結合した化合物

Also Published As

Publication number Publication date
AR012193A1 (es) 2000-09-27
JP2009280596A (ja) 2009-12-03
IL123716A0 (en) 1998-12-06
WO1998043646A1 (en) 1998-10-08
HUP0002742A2 (hu) 2001-05-28
CZ298105B6 (cs) 2007-06-27
RU2222330C2 (ru) 2004-01-27
JP4377456B2 (ja) 2009-12-02
CA2284551C (en) 2007-06-12
DE69833645T2 (de) 2006-08-24
HK1023293A1 (en) 2000-09-08
DE69833645D1 (de) 2006-04-27
NO994673L (no) 1999-11-17
ID22283A (id) 1999-09-30
CZ343199A3 (cs) 2000-04-12
KR20010005677A (ko) 2001-01-15
TW587938B (en) 2004-05-21
ATE318604T1 (de) 2006-03-15
NZ337618A (en) 2000-06-23
IL123716A (en) 2001-03-19
CN1251526A (zh) 2000-04-26
HUP0002742A3 (en) 2003-03-28
EP0969845A1 (en) 2000-01-12
JP2001521497A (ja) 2001-11-06
PT969845E (pt) 2006-05-31
AU7213998A (en) 1998-10-22
PL191449B1 (pl) 2006-05-31
PL335890A1 (en) 2000-05-22
CN1226036C (zh) 2005-11-09
CA2284551A1 (en) 1998-10-08
BR9808077A (pt) 2000-03-08
TR199902334T2 (xx) 2000-01-21
AU726194B2 (en) 2000-11-02
EP0969845B1 (en) 2006-03-01
JP5023315B2 (ja) 2012-09-12
NO994673D0 (no) 1999-09-24
DK0969845T3 (da) 2006-06-19
KR100577865B1 (ko) 2006-05-10

Similar Documents

Publication Publication Date Title
ES2259207T3 (es) Nuevas combinaciones terapeuticas de mirtazapina y agentes antipsicoticos para el tratamiento o profilaxis de trastornos psicoticos.
US6150353A (en) Therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
Bloch et al. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt?
ES2599227T3 (es) Neuroprotección en enfermedades desmielinizantes
US20160051494A1 (en) Multi-dose medication kit for treating anaphylaxis
JP2019031551A (ja) 女性胃不全麻痺に関係する症状の処置
CN1176652C (zh) 褪黑激素在治疗疾病方面的应用
KR0178762B1 (ko) 특정 인돌 유도체의 신규 의약적 용도 및 그를 함유하는 제약 조성물
ES2214305T3 (es) Utilizacion de la ciamemazina en el tratamiento de la eliminacion brusca de las benzodiazepinas.
ES2326078T3 (es) Medicamento destinado al sindrome de la disfuncion de integracion.
BreivikM. D et al. Piroxicam, acetylsalicylic acid and placebo for postoperative pain
ES2284830T3 (es) Uso de quetiapina para el tratamiento de la cocaina.
HK1023293B (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
MXPA99008791A (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
JP7634002B2 (ja) 新規小児用配合剤
ES2287512T3 (es) Utilizacion combinada de metilfenidato y melatonina para el tratamiento de la enfermedad de hiperactividad con deficit de atencion.
AR020167A1 (es) Metodo para la prevencion del inicio del asma
Mahmood A double‐blind trial of a phenothiazine compound in the treatment of clinical crisis of sickle cell anaemia
Canning et al. Comparison of the use of nalbuphine and fentanyl during third molar surgery
ES2309148T3 (es) Composiciones farmaceuticas que comprenden pravastatina para reducir los niveles de colesterol ldl.
RU98109932A (ru) Применение 1-(2-нафт-2-илэтил)-4-(3-трифторметилфенил)-1,2,3,6-тетрагидропиридина для получения лекарственных средств, предназначенных для лечения бокового амиотрафического склероза
WO1999034799A1 (en) Use of diphenylmethylene piperidine derivatives in the manufacture of a medicament for the treatment of movement disorders